Menu
Back to User profile » Dr Robert Klamroth
Papers published by Dr Robert Klamroth:
Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials
Mancuso ME, Eriksson D, Falk A, Hakimi Z, Wojciechowski P, Wdowiak M, Klamroth R
Journal of Blood Medicine 2023, 14:427-434
Published Date: 27 July 2023
Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
Klamroth R, Hampton K, Saulyte Trakymienė S, Korsholm L, Carcao M
Patient Preference and Adherence 2021, 15:2443-2454
Published Date: 4 November 2021
Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
Vashi P, Batt K, Klamroth R, Mancuso ME, Majewska R, Tiede A, Mantovani LG
Journal of Blood Medicine 2021, 12:935-943
Published Date: 1 November 2021
Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials
Astermark J, Wojciechowski P, Aballéa S, Hakimi Z, Nazir J, Klamroth R
Journal of Blood Medicine 2021, 12:613-621
Published Date: 14 July 2021
Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials
Klamroth R, Wojciechowski P, Aballéa S, Diamand F, Hakimi Z, Nazir J, Abad-Franch L, Lethagen S, Santagostino E, Tarantino MD
Journal of Blood Medicine 2021, 12:115-122
Published Date: 25 February 2021
The Patient Experience of Gene Therapy for Hemophilia: Qualitative Interviews with Trial Patients
Miesbach W, Klamroth R
Patient Preference and Adherence 2020, 14:767-770
Published Date: 22 April 2020
Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study
Simpson ML, Kulkarni R, Escuriola Ettingshausen C, Medom Meldgaard R, Cooper DL, Klamroth R
Journal of Blood Medicine 2019, 10:391-398
Published Date: 13 November 2019
Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
Batt K, Gao W, Ayyagari R, Deschaseaux C, Vashi PB, Yao Z, Wang Y, Kessabi S, Klamroth R
Journal of Blood Medicine 2019, 10:147-159
Published Date: 20 June 2019